Entrada Historical Income Statement

TRDA Stock  USD 19.83  0.46  2.37%   
Historical analysis of Entrada Therapeutics income statement accounts such as Selling General Administrative of 19.2 M, Total Revenue of 135.5 M, Gross Profit of 30.6 M or Other Operating Expenses of 70.2 M can show how well Entrada Therapeutics performed in making a profits. Evaluating Entrada Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Entrada Therapeutics's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Entrada Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Entrada Therapeutics is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.

About Entrada Income Statement Analysis

Entrada Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Entrada Therapeutics shareholders. The income statement also shows Entrada investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Entrada Therapeutics Income Statement Chart

At present, Entrada Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 16 M, whereas Selling General Administrative is forecasted to decline to about 19.2 M.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Entrada Therapeutics. It is also known as Entrada Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Entrada Therapeutics income statement and represents the costs associated with goods and services Entrada Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from Entrada Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Entrada Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.At present, Entrada Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 16 M, whereas Selling General Administrative is forecasted to decline to about 19.2 M.
 2021 2023 2024 (projected)
Depreciation And Amortization1.1M2.8M3.0M
Interest Income2.6M15.2M16.0M

Entrada Therapeutics income statement Correlations

0.990.910.720.980.780.17-0.180.170.790.210.990.780.770.280.810.040.930.940.95
0.990.930.740.980.790.15-0.20.150.810.190.990.790.790.260.770.010.940.940.95
0.910.930.910.850.92-0.22-0.55-0.220.92-0.180.880.920.92-0.110.54-0.360.750.830.84
0.720.740.910.620.99-0.5-0.75-0.50.98-0.460.660.990.99-0.40.3-0.60.470.70.7
0.980.980.850.620.690.33-0.030.330.710.371.00.690.680.430.850.190.980.950.96
0.780.790.920.990.69-0.38-0.66-0.381.0-0.350.731.01.0-0.280.37-0.50.570.790.78
0.170.15-0.22-0.50.33-0.380.931.0-0.341.00.27-0.38-0.40.990.590.980.480.270.27
-0.18-0.2-0.55-0.75-0.03-0.660.930.93-0.620.92-0.09-0.66-0.670.890.340.980.14-0.07-0.07
0.170.15-0.22-0.50.33-0.381.00.93-0.341.00.27-0.38-0.40.990.590.980.480.270.27
0.790.810.920.980.711.0-0.34-0.62-0.34-0.30.751.00.99-0.240.39-0.460.60.810.81
0.210.19-0.18-0.460.37-0.351.00.921.0-0.30.31-0.35-0.361.00.620.980.520.310.31
0.990.990.880.661.00.730.27-0.090.270.750.310.730.720.370.820.130.970.950.96
0.780.790.920.990.691.0-0.38-0.66-0.381.0-0.350.731.0-0.280.37-0.50.570.790.78
0.770.790.920.990.681.0-0.4-0.67-0.40.99-0.360.721.0-0.30.35-0.510.560.780.77
0.280.26-0.11-0.40.43-0.280.990.890.99-0.241.00.37-0.28-0.30.690.970.570.370.37
0.810.770.540.30.850.370.590.340.590.390.620.820.370.350.690.520.850.780.79
0.040.01-0.36-0.60.19-0.50.980.980.98-0.460.980.13-0.5-0.510.970.520.340.130.13
0.930.940.750.470.980.570.480.140.480.60.520.970.570.560.570.850.340.920.93
0.940.940.830.70.950.790.27-0.070.270.810.310.950.790.780.370.780.130.921.0
0.950.950.840.70.960.780.27-0.070.270.810.310.960.780.770.370.790.130.931.0
Click cells to compare fundamentals

Entrada Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.44
Revenue Per Share
6.074
Quarterly Revenue Growth
(0.55)
Return On Assets
0.0695
Return On Equity
0.1642
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.